1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Unilever PLC
  6. News
  7. Summary
    ULVR   GB00B10RZP78

UNILEVER PLC

(ULVR)
  Report
Delayed Quote. Delayed London Stock Exchange - 05/20 11:35:25 am
3516.5 GBX   +1.88%
03:12aInflation crimps Indian firms as rural millions cut spending
RE
05/19European ADRs Move Higher in Thursday Trading
MT
05/19London's FTSE 100 tumbles on global slowdown worries
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

OUCH

01/18/2022 | 01:21am EDT

UNILEVER shares took a battering yesterday as investors fled the FTSE 100 giant following news of three failed bids for Panadol-maker GLAXOSMITHKLINE's (GSK) consumer healthcare group.

Shares plunged as much as seven per cent in early trading making the firm the fastest faller on the FTSE 100, before it regained some ground later in the day.

Reports of the failed £50bn cash-andshare approach from Marmite-maker Unilever spurred more of a hate it than love it reaction from the markets as GSK shares soared faster than any FTSE 250 firm, peaking at nearly five per cent above their opening price.

The rebuffed bids for GSK's consumer portfolio, which includes Sensodyne and Panadol, have now fuelled speculation of a bidding war erupting with both consumer goods giants and private equity firms reportedly circling the business.

Advent International, CVC Capital Partners and KKR have all previously shown interest in snapping up the consumer brands, according to Bloomberg, and bankers are preparing a hefty £25bn finance package for a private equity swoop.

Laura Hoy, an equity analyst at Hargreaves Lansdown, told City A.M. that

Unilever's bids had also "shone a light" on the business to other potential consumer healthcare suitors.

She told City A.M.: "The Unilever bid was not well received by the market because Unilever on the surface doesn't look the best home, but it would be remiss of me to suggest that some of the other big names are not now looking at this."

£ CONTINUED ON PAGE 3

CONTINUED FROM PAGE 1 GSK shareholders also rounded on the offer from Unilever yesterday. Richard Buxton at Jupiter Capital Management, a top 30 shareholder in GSK, told the Financial Times: "The idea of letting the goons at Unilever run it is laughable."

Unilever Boss Alan Jope mounted a defence of the bid and rolled out a long-term plan to ramp up growth in its health, beauty and hygiene business, while pledging to offload slower-growing products.

The firm doubled down on the GSK bids, saying the portfolio was "a strong strategic fit" that offered a platform for growth in the US, China, and India.

"We believe that this would be an attractive and synergistic combination for the shareholders of Unilever, which would also deliver value and certainty for the shareholders of GSK and Pfizer,"

it said in a market update yesterday Analysts expect a successful bid would need to be around £5-10bn bigger.

(c) 2022 City A.M., source Newspaper

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 1.87% 1764 Delayed Quote.9.80%
UNILEVER PLC 1.88% 3516.5 Delayed Quote.-10.87%
All news about UNILEVER PLC
03:12aInflation crimps Indian firms as rural millions cut spending
RE
05/19European ADRs Move Higher in Thursday Trading
MT
05/19London's FTSE 100 tumbles on global slowdown worries
RE
05/19European shares lower as retailers, food and beverage stocks lead falls
RE
05/19UNILEVER PLC : Ex-dividend day for interim dividend
FA
05/18UNITED WE STAND : Unilever Supports Systemic Change for LGBTQI+ Communities
BU
05/18Indian Indices Close in Red Midweek; Power Grid Corporation of India Drops 5%
MT
05/17WALL STREET STOCK EXCHANGE : Finding the tipping point
05/17MARKETSCREENER'S WORLD PRESS REVIEW : May 17, 2022
05/17SocGen Downgrades Unilever To Sell From Buy, Cuts PT
MT
More news
Analyst Recommendations on UNILEVER PLC
More recommendations
Financials
Sales 2022 57 621 M 60 788 M 60 788 M
Net income 2022 5 639 M 5 949 M 5 949 M
Net Debt 2022 23 916 M 25 231 M 25 231 M
P/E ratio 2022 19,8x
Yield 2022 4,09%
Capitalization 106 B 112 B 112 B
EV / Sales 2022 2,25x
EV / Sales 2023 2,17x
Nbr of Employees 148 012
Free-Float 95,5%
Chart UNILEVER PLC
Duration : Period :
Unilever PLC Technical Analysis Chart | ULVR | GB00B10RZP78 | MarketScreener
Technical analysis trends UNILEVER PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 41,55 €
Average target price 47,16 €
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
Alan Jope Chief Executive Officer & Executive Director
Graeme David Pitkethly Chief Financial Officer & Executive Director
Nils Smedegaard Andersen Chairman
Richard Slater Chief Research & Development Officer
Nitin Paranjpe Chief Operating, Transformation & People Officer
Sector and Competitors
1st jan.Capi. (M$)
UNILEVER PLC-10.87%110 074
PROCTER & GAMBLE COMPANY-13.38%339 980
THE ESTÉE LAUDER COMPANIES INC.-36.42%84 112
HINDUSTAN UNILEVER LIMITED-1.45%68 646
COLGATE-PALMOLIVE COMPANY-11.98%62 946
RECKITT BENCKISER GROUP PLC-3.03%54 973